Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

108.50 +0.50 (+0.46%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 23,268,132
Open 108.85
Bid (Size) 108.50 (18)
Ask (Size) 109.15 (1)
Prev. Close 108.00
Today's Range 107.30 - 110.16
52wk Range 66.01 - 119.96
Shares Outstanding 1,253,809,440
Dividend Yield 2.91%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire

Performance

YTD
+18.1%
+18.1%
1 Month
+1.6%
+1.6%
3 Month
+1.6%
+1.6%
6 Month
+16.2%
+16.2%
1 Year
+53.5%
+53.5%

More News

Read More
FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag
Via Benzinga
Exposures Product Safety
GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering
Via Chartmill
Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV Prevention
Via Stocktwits
Exposures Product Safety
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Gilead Sciences Wins Approval For Highly Effective HIV Prevention Drug
Via Investor's Business Daily
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
From Gilead Sciences, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) – A potential undervalued opportunity in biopharma
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased
Via Stocktwits
Exposures Product Safety
1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar
Via StockStory
Exposures COVID-19
Why Gilead Scinces Stock Tumbled on Tuesday
Via The Motley Fool
Exposures Product Safety
Gelteq Stock Soars On Deal With Healthy Extracts For Product Distribution In North America: Retail Chatter Explodes
Via Stocktwits
Exposures Product Safety
US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence
Via Stocktwits
Exposures Product Safety
2 Reasons to Like GILD (and 1 Not So Much)
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
Via Benzinga
Exposures Product Safety
1 Healthcare Stock Worth Your Attention and 2 to Turn Down
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating
Via Stocktwits
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance
Via Stocktwits
Topics Government
Exposures Political Product Safety
GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering
Via Chartmill

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 108.50
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 06/20/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 136.04B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 136B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.